|
gptkbp:instanceOf
|
gptkb:drug
gptkb:anticonvulsant
|
|
gptkbp:ATCCode
|
N03AD01
|
|
gptkbp:bioavailability
|
almost complete
|
|
gptkbp:brand
|
gptkb:Zarontin
|
|
gptkbp:CASNumber
|
77-67-8
|
|
gptkbp:chemicalClass
|
succinimide
|
|
gptkbp:contraindication
|
hypersensitivity to succinimides
|
|
gptkbp:discoveredBy
|
gptkb:Parke-Davis
|
|
gptkbp:eliminationHalfLife
|
30-60 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstPassMetabolism
|
yes
|
|
gptkbp:form
|
gptkb:sugar
capsule
|
|
gptkbp:hasMolecularFormula
|
C7H11NO2
|
|
gptkbp:introducedIn
|
1958
|
|
gptkbp:IUPACName
|
3-ethyl-3-methyl-pyrrolidine-2,5-dione
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks T-type calcium channels
|
|
gptkbp:meltingPoint
|
110-112°C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
C (US)
B2 (Australia)
|
|
gptkbp:proteinBinding
|
not significant
|
|
gptkbp:PubChem_CID
|
3285
DB00593
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
aplastic anemia
nausea
vomiting
drowsiness
urticaria
leukopenia
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:synonym
|
gptkb:Emeside
gptkb:Suxilep
|
|
gptkbp:UNII
|
5SEH9X1D1E
|
|
gptkbp:usedFor
|
absence seizures
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Anticonvulsants
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ethosuximide
|